Cargando…
HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance
Although the medical treatments of sarcoma have evolved in the last years, a significant portion of patients develops recurrence after therapies suggesting the need to identify novel targets to improve the treatments. By the use of patient-derived and established cell lines from liposarcoma, as well...
Autores principales: | Loria, Rossella, Laquintana, Valentina, Bon, Giulia, Trisciuoglio, Daniela, Frapolli, Roberta, Covello, Renato, Amoreo, Carla Azzurra, Ferraresi, Virginia, Zoccali, Carmine, Novello, Mariangela, Del Bufalo, Donatella, Milella, Michele, Biagini, Roberto, D’Incalci, Maurizio, Falcioni, Rita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224401/ https://www.ncbi.nlm.nih.gov/pubmed/29980789 http://dx.doi.org/10.1038/s41388-018-0394-x |
Ejemplares similares
-
New activities for the anti-tumor agent trabectedin: taking two birds with one stone
por: D'Incalci, Maurizio, et al.
Publicado: (2013) -
Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB
por: Demchenko, Yulia N., et al.
Publicado: (2014) -
Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022) -
NFkB Pathway and Hodgkin Lymphoma
por: Jardin, Fabrice
Publicado: (2022) -
A critical role for the NFkB pathway in multiple myeloma
por: Demchenko, Yulia N., et al.
Publicado: (2010)